EGFR and non-small cell lung carcinoma: Osimertinib is the first EGFR-TKI approved by the United States (U.S.)Food and Drug Administration (FDA) for the treatment of T790M-mutated metastatic NSCLC because of its promising efficacy (60% objective response rate (ORR) and 10 months of progression-free survival), as shown in serial AURA trials [8–11].